Latest / CME Outfitters Medical Education / Cleared for Takeoff: An All-Hands-on Deck Approach to Building Confidence and Competence in S1P Receptor Modulator Initiation for Ulcerative Colitis
Transcript
- 0:01SPEAKER_01: Hello, on behalf of CME Outfitters, I would like to welcome you to today's educational activity titled Cleared for Takeoff, an all hands-on-deck approach to building confidence and competence in S1P receptor modulator initiation for patients with ulcerative colitis.
- 0:19SPEAKER_01: This program is supported by an educational grant from Pfizer.
- 0:23SPEAKER_01: This activity may include discussions of products or devices that are not currently labeled for use by the FDA.
- 0:30SPEAKER_01: As faculty, we have been informed of our responsibility to disclose to the audience if we will be discussing off-label or investigational uses of products or devices.
- 0:40SPEAKER_01: I'm Dr.
- 0:41SPEAKER_01: David Rubin.
- 0:42SPEAKER_01: I'm a professor of medicine at the University of Chicago, where I also direct our inflammatory bowel disease center.
- 0:48SPEAKER_01: And I'm joined by two of my esteemed colleagues and friends, and will also be joined by some other expert colleagues throughout this program in video clips.
- 0:57SPEAKER_01: My first colleague is Dr.
- 0:58SPEAKER_01: Josh Steinberg, who's director of inflammatory bowel disease at Gastroenterology of the Rockies in Denver, Colorado.
- 1:05SPEAKER_01: And my second colleague is Ms.
- 1:07SPEAKER_01: Kimberly Orlick, who is the Vice President of Advanced Practice Providers at United Digestive in Atlanta, Gastro Neurology Associates, obviously in Atlanta, Georgia.
- 1:18SPEAKER_01: Hi, Josh.
- 1:19SPEAKER_01: Hi, Kim.
- 1:20SPEAKER_06: Hi.
- 1:20SPEAKER_06: Thanks so much for having us.
- 1:22SPEAKER_06: Yes.
- 1:23SPEAKER_06: Really happy to be here.
- 1:24SPEAKER_06: Thank you.
- 1:25SPEAKER_01: Well, delighted to be doing this with you.
- 1:27SPEAKER_01: And it's obviously a very important topic for us.
- 1:29SPEAKER_01: So our learning objectives for this program are number one, to assess the rationale for recommended baseline testing prior to sphenocine-1 phosphate receptor modulator treatment initiation in patients with ulcerative colitis.
- 1:45SPEAKER_01: Number two, to incorporate optimized strategies for cardiovascular, dermatologic, and ophthalmic assessment, utilizing appropriate tools when determining patient eligibility for S1P receptor modulator therapy.
- 2:00SPEAKER_01: And number three, to integrate interprofessional multidisciplinary frameworks into real-world workflows for assessment of patients with UC to optimize the delivery of S1P receptor modulator therapy.
- 2:13SPEAKER_01: Let's start with part one, the pre-flight check, where we'll build the case for S1P receptor modulator initiation in ultra tipcolitis.
- 2:22SPEAKER_01: And before we get into the data, it helps to level set how S1P receptor modulators actually work.
- 2:29SPEAKER_01: I want to refer to this wonderful cartoon that highlights the selective lymphocyte sequestration of this particular mechanism.
- 2:38SPEAKER_01: The way S1P receptor modulators are believed to work is they essentially block the ability of activated lymphocytes to egress out of lymph nodes where they are turned on and then migrate through the lymphatics to the gut.
- 2:54SPEAKER_01: So if we prevent their ability to leave those lymph nodes, they stay in the lymph nodes and they don't go to the intestine where that cellular immune system is being driven.
- 3:04SPEAKER_01: When we provide an S1P receptor modulator that blocks the ability to sense the signaling molecules that are calling those cells to an inflamed area of our body, it essentially shuts down that mechanism, and then the rest of the immune process downstream is also turned off.
- 3:24SPEAKER_01: The S1P receptor modulators that are available for moderately to severely active ulcerative colitis in the United States include ozonomod and atrosomod.
- 3:34SPEAKER_01: They're both small molecules, and they both offer oral delivery that is once daily.
- 3:40SPEAKER_01: And my colleagues will be talking a little bit more about that.
- 3:43SPEAKER_01: But because of this unique mechanism and the fact that they are small molecules and not monoclonal antibodies, it does offer some benefits as well as convenience to the patients who have ulcerative colitis.
- 3:57SPEAKER_01: Josh, can you orient us to where ozonomod and atrosomod fit within this specific class?
- 4:04SPEAKER_08: Certainly.
- 4:05SPEAKER_08: Thank you, David.
- 4:06SPEAKER_08: So we have two uh S1P receptor modulators that are currently FDA approved for moderate to severely active ulcerative colitis.
- 4:13SPEAKER_08: We have ozanomod and we have atrasomod.
- 4:16SPEAKER_08: You can see the receptor targets listed here.
- 4:18SPEAKER_08: There's several other S1P receptor modulators that are under investigation for ulcerative colitis, as well as several others that are used for other indications, specifically multiple sclerosis.
- 4:28SPEAKER_08: But we have two that are currently being used for moderate severely active UC.
- 4:32SPEAKER_08: And first we'll start with ozonmod.
- 4:34SPEAKER_08: We're going to talk about uh the efficacy data first, and then we'll dive more into safety, and then we'll get more into the nitty-gritty of how you actually start your patients on S1Ps.
- 4:43SPEAKER_08: So, first and foremost, let's look at OzonMod.
- 4:46SPEAKER_08: This is efficacy as induction and maintenance in ultravocalitis.
- 4:49SPEAKER_08: This was based on the phase three uh trial, True North.
- 4:52SPEAKER_08: This was the registrational trial that led to the FDA approval of Ozanmod for moderate spherely active UC.
- 4:58SPEAKER_08: You can see induction as well as maintenance data here.
- 5:01SPEAKER_08: And these are key efficacy endpoints.
- 5:04SPEAKER_08: First and foremost, starting with clinical remission at the end of a 10-week induction period, as compared to placebo, we see clear superiority, 18.4% versus six in placebo.
- 5:13SPEAKER_08: And then across other endpoints with induction, including clinical response, endoscopic improvement, as well as mucosal healing during that 10-week induction period.
- 5:22SPEAKER_08: What about maintenance up to that 52-week period?
- 5:24SPEAKER_08: Again, that key endpoint of clinical remission of Zanman Met, 37% versus 18.5% for placebo.
- 5:31SPEAKER_08: And across these other key secondary endpoints, clinical response, endoscopic improvement, maintenance of remission, importantly, leucocorticoid-free remission, as well as mucosal healing and durable remission, demonstrating this durable clinical as well as the endoscopic benefit through induction as well as through maintenance at week 52.
- 5:51SPEAKER_08: Many patients, when you're starting them on any therapy, are going to ask you how soon might this treatment that you're starting me on, how soon will it start to work?
- 5:59SPEAKER_08: And we can see here early symptomatic response as well as symptomatic remission with ozonomat.
- 6:05SPEAKER_08: And we see that specifically symptomatic response tends to precede symptomatic remission.
- 6:09SPEAKER_08: We're looking at specifically with ULSHIV colitis, the rectal bleeding and stool frequency scores that were observed early during induction.
- 6:17SPEAKER_08: So looking at induction data here through week zero through week 10, both ozonomatic groups in the induction trial and true north clearly met these endpoints of symptomatic response and symptomatic remission as reflected by these rectal bleeding and stool frequency score reductions as compared to placebo.
- 6:35SPEAKER_08: And at the end of that 10-week induction period, you can clearly see these deltas start to widen as patients gain more exposure to the active agent, in this case, ozonomod.
- 6:46SPEAKER_01: And you can see how quickly it works.
- 6:49SPEAKER_01: Some people think that a cellular mechanism might be slow, but I think what we're seeing with both ozonomod and introstomod is a fairly rapid onset.
- 6:58SPEAKER_08: Absolutely.
- 6:58SPEAKER_08: Based on these data, as soon as we too, we're starting to see some of these uh key differentiators with uh symptomatic response and subsequently symptomatic remission.
- 7:07SPEAKER_08: Now, what about where these treatments might be positioned?
- 7:10SPEAKER_08: So we're looking at data of ozonomod efficacy based on prior biologic class.
- 7:15SPEAKER_08: Again, this is the phase three true North Clinical trial data.
- 7:18SPEAKER_08: And what we're seeing is efficacy that's demonstrated across prior anti-TNF as well as prior vitalismab exposure.
- 7:24SPEAKER_08: And there was a sustained benefit through maintenance in these biologic experience patients.
- 7:29SPEAKER_08: On the top, we're seeing the induction data, and the bottom we're seeing our maintenance data.
- 7:34SPEAKER_08: And this is basically the response rates based on prior betalismab, anti-TNF, or both of those previous treatments being exposed to the patient prior to enrollment and this ozanid trial.
- 7:45SPEAKER_08: And essentially what we're seeing is that in these patients, regardless of whether they had exposure to the anti-TNF, to betalismab or both, there were still robust clinical response as well as clinical remission rates in both induction as well as maintenance.
- 8:04SPEAKER_08: Many patients in your practice or in your clinic, when you see them, they might have been on one biologic in the past, two or more.
- 8:12SPEAKER_08: And what we're seeing here in the phase three true north data is that regardless of the number of biologic exposures, again, we're still seeing these response rates in terms of clinical as well as endoscopic responses, but really focusing on the clinical remission and clinical response rates here, with both induction with ozonomod as well as maintenance with ozonomad.
- 8:31SPEAKER_08: We do tend to see more robust response rates in those who have had less biologic exposure.
- 8:36SPEAKER_08: And what we'll show you on the next slide is that even in patients who are biologically naive, we tend to see an even more impressive response.
- 8:47SPEAKER_08: What we're focusing on here is ozonomod efficacy in patients who are naive to advanced therapy, meaning these patients had no prior exposure to Vitalismab or anti-TNFs like infliximab, adulumab, et cetera.
- 9:00SPEAKER_08: And clearly what we're seeing here, and this is the maintenance data, so up to week 52, are very robust response rates in terms of clinical remission, response, as well as endoscopic endpoints and storic-free endpoints, as well as durable remission in these patients who are biologic naive or advanced therapy naive.
- 9:18SPEAKER_08: If we break it down even further, right, when we classify our patients as having moderate or severely active disease based on their modified MAO scores, in the patients who had moderate disease as compared to severe disease at baseline, those patients with moderate disease exposed to ozanomod through the phase three true north clinical trial had an even more robust response in terms of their response rates clinically, with clinical remission, clinical response, as well as endoscopic improvement.
- 9:45SPEAKER_08: I think all this shows that perhaps positioning this particular therapy and that patient who has more moderate disease as opposed to very severe disease, as well as this that patient who has had no prior biologic exposure and advanced therapy naive patient might be a key patient population where this particular agent, ozanomat, an S1P receptor modulator, might have significant success.
- 10:08SPEAKER_08: That being said, it still can be used as a second or third blind advanced therapy in your patients with prior biologic failure.
- 10:14SPEAKER_01: Josh, do you think that this reflects progression of ulcerative colitis in a true biologic refractoriness, or are we selecting out more refractory patients who get into clinical trials?
- 10:26SPEAKER_08: Yeah, I think with more and more advanced therapies that are now FDA approved and available for our patients, we tend to see these more complex and refractory patients at baseline, especially if you are an IBD specialist or in a big IBD center.
- 10:40SPEAKER_08: So we're really trying to identify where we could utilize this MLA, the S1P receptor modulator, to use it to our patient's advantage, where we can get uh the most efficacy early on in their disease course prior to them developing more progressed or severe complications and really using this as a first-line therapy, if possible, in our patients, uh, so that we can achieve and maintain that success.
- 11:09SPEAKER_07: All right, so now we're gonna look at the longer-term data.
- 11:12SPEAKER_08: We talked about induction at 10 weeks, maintenance at 52 weeks, but with ozonomod, we do have efficacy data that is sustained up to three years.
- 11:20SPEAKER_08: This is looking at our open label extension data with ozonomod.
- 11:24SPEAKER_08: So this is a total of 146 weeks of treatment, so additional 94 weeks after that 52-week period.
- 11:32SPEAKER_08: You can see the patients on ozonomad had a clinical response that was durable.
- 11:36SPEAKER_08: 91.4% of those patients maintained that response, and about 70% maintained a clinical remission.
- 11:42SPEAKER_08: And importantly, about 68% of those patients were able to maintain and achieve that corticosteroid free remission.
- 11:48SPEAKER_08: And even more importantly, with safety, no new safety signals, and we'll talk more about safety later in this discussion, but no new safety signals as patients had longer exposure to ozonomod.
- 11:59SPEAKER_01: That's terrific, Josh.
- 12:00SPEAKER_01: Thank you so much for covering the efficacy data for ozonomod.
- 12:04SPEAKER_01: So again, ozonomod, a small molecule, is a selective S1P1 and S1P5 receptor modulator.
- 12:12SPEAKER_01: And it is one of the two therapies currently available in the US in patients with moderately to severely active UC.
- 12:19SPEAKER_01: Atrosomod is the other one, and this is an S1P1, S1P4, and S1P5 receptor modulator.
- 12:27SPEAKER_01: And Kim's going to teach us a little bit about that.
- 12:29SPEAKER_01: So, Kim, take it away.
- 12:31SPEAKER_06: Thanks, Dr.
- 12:31SPEAKER_06: Rubin, and thank you for pointing out that difference.
- 12:34SPEAKER_06: I also do want to remind everybody as we start to talk about the elevate studies, that the elevate studies are slightly different than true north, particularly as we look at elevate UC52, just reminding listeners that this is a treat-through study design.
- 12:47SPEAKER_06: And so this means that patients at the end of induction are continued into the maintenance arm on their same therapy, regardless of if they had that initial clinical response at the end of induction.
- 12:59SPEAKER_06: The induction timeline here was also slightly different at 12 weeks versus 10 weeks.
- 13:03SPEAKER_06: But again, even the patients who didn't respond at the end of induction are moved into maintenance in the study compared to the re-randomization design of TrueNorth.
- 13:12SPEAKER_06: So what we see on this first slide is at both 12 and 52 weeks, a Trasmon met its primary endpoint at clinical remission with really nice deltas.
- 13:20SPEAKER_06: We see a delta of almost 20% at that 12-week clinical remission and 25% at 52 weeks.
- 13:27SPEAKER_06: So this shows us how fast this therapy can work, and we'll talk a little bit more about the rapidity of efficacy, but also the sustained efficacy of this therapy in regards to clinical remission.
- 13:37SPEAKER_06: Additionally, we can see at the bottom that a Tresmod met all of its key secondary endpoints at weeks 12 and 52, and that includes endoscopic and histologic endpoints.
- 13:49SPEAKER_06: Now we're going to look at a Tresmod efficacy by baseline endoscopic severity.
- 13:54SPEAKER_06: So this post hoc analysis of the elevate trials examined whether baseline endoscopic severity, meaning mayo endoscopic subscore two versus three, influenced the response to a Tresmod.
- 14:05SPEAKER_06: The first thing I want to highlight is the early separation from placebo with regards to both clinical remission and clinical response, regardless of that baseline endoscopic severity score of two or three, and regardless of baseline modified mayo score.
- 14:20SPEAKER_06: We see that symptomatic improvement precedes remission.
- 14:24SPEAKER_06: Those with endoscopic scores of two achieve clinical remission and clinical response faster than those with mayo endoscopic scores of three.
- 14:32SPEAKER_06: But those with severe endoscopic disease, we can see here they continue to have improvement in their clinical remission rates from weeks 12 to 52, regardless of MS MMS.
- 14:42SPEAKER_06: In clinical practice, this is where I really think about possibly giving patients with severe endoscopic disease more time before we start to deem them a failure or a non-responder to this oral therapy.
- 14:55SPEAKER_06: Another unique thing about the clinical studies of Elevate UC is this is the only phase three UC trials that include patients with isolated ulcerative proctitis.
- 15:06SPEAKER_06: This is typically a patient population that has been excluded from biologic and small molecule trials.
- 15:12SPEAKER_06: In these studies, about 8% of the total study population had limited proctitis.
- 15:17SPEAKER_06: Here, what we can see is statistically significant clinical remission data in the atrazomod group who have only proctitis at both 12 and 52 weeks.
- 15:27SPEAKER_06: Here, seeing clinical remission in that proctitis patients at almost 43% at just 12 weeks and over 44% at 52 weeks.
- 15:36SPEAKER_06: Again, seeing the sustainability of efficacy and that rapidity of onset.
- 15:40SPEAKER_06: This is also a really good reminder that disease extent should not be the sole determinant of treatment intensity, as we all know that patients with isolated proctitis can have significant symptom burden.
- 15:53SPEAKER_06: And really, we need to work with advanced therapies like a Trazomod to help them achieve that clinical remission.
- 16:00SPEAKER_01: So, Kim, you highlight two important distinctions in the study design with the trostomod.
- 16:05SPEAKER_01: First, that it was a treat-through study, which is a little bit like the real world kind of study, what you would do when you put a patient on a therapy.
- 16:12SPEAKER_01: If it's working, you keep going, and we're not randomizing and withdrawing the treatment in favor of a placebo and maintenance.
- 16:19SPEAKER_01: And then you point out the isolated proctitis data.
- 16:24SPEAKER_01: Most of our phase three trials in ulcerative colitis excluded proctitis.
- 16:29SPEAKER_01: Do you think this is unique to this mechanism that it worked in isolated proctitis, or they were just brave enough to study it?
- 16:36SPEAKER_06: I'll be honest, I don't know that I can say it's unique to this mechanism, but I appreciate that I think they were brave enough to study it.
- 16:42SPEAKER_06: I think all of us in our clinical practice have seen great success with other advanced therapies with proctitis.
- 16:48SPEAKER_06: But I will also say my patients with proctitis love when I tell them that patients like them have been studied and that we have efficacy data in the subgroup of patients like them.
- 16:57SPEAKER_01: Yeah, I completely agree with you.
- 17:00SPEAKER_06: Thanks for calling that out.
- 17:01SPEAKER_06: So here at this next slide, we're going to look at a Trazmod efficacy looking at both moderate and severe endoscopic disease.
- 17:08SPEAKER_06: And essentially what we see here is regardless of past treatment exposure or endoscopic severity, again, either two or three, clinical remission and clinical response is seen at higher efficacy compared to placebo at both weeks 12 and 52.
- 17:24SPEAKER_06: Those with moderate endoscopic disease, again, we see that they achieve clinical remission and clinical response faster than those with severe endoscopic disease.
- 17:34SPEAKER_06: Another thing you can see on these graphs is that in those patients with moderate endoscopic disease at baseline, their prior treatment exposure doesn't really have a significant impact on their week 12 or 52 endpoints.
- 17:47SPEAKER_06: But those with severe endoscopic disease, as I mentioned before, you can see it might take a little bit longer for clinical remission to get there.
- 17:55SPEAKER_06: And so what I really want to highlight again is the durability of the efficacy that we see across all of these subgroups in both clinical response and clinical remission.
- 18:08SPEAKER_06: We all know our goal is not just to get patients into remission, but it is really to get them into remission and keep them off steroids.
- 18:15SPEAKER_06: So here we're looking at the durable corticosteroid-free remission with a Tresomod.
- 18:20SPEAKER_06: And essentially, again, what we see is regardless of baseline endoscopic severity, and we see the sustained steroid-free clinical remission.
- 18:28SPEAKER_06: And so on the left-hand side, we see moderate and severe, both of these patient populations are able to achieve again with nite deltas two placebo, great corticosteroid-free clinical remission.
- 18:39SPEAKER_06: And then the right hand side, regardless of that two or three endoscopic disease or their baseline modified mayo score, we still see really great sustained long-term steroid-free remission through 52 weeks.
- 18:52SPEAKER_06: I know, Dr.
- 18:53SPEAKER_06: Rubin and Dr.
- 18:53SPEAKER_06: Steinberg, both of you talked when it came to a xenomod about how quickly patients can experience symptom relief.
- 18:59SPEAKER_06: And while our goals might think about more of the long term in addition to the short term, I think you both will agree the short term is really what the patients care about.
- 19:06SPEAKER_06: And so what we're looking at here is the rapidity of symptomatic improvement with a trazomod.
- 19:12SPEAKER_06: And I want to call out this was based on patient e-diaries during the first 28 days of therapy.
- 19:18SPEAKER_06: What we see is the first statistically significant difference between a trazomod and placebo was symptomatic response, which was seen as early as day two.
- 19:27SPEAKER_06: And Dr.
- 19:27SPEAKER_06: Rubin, you talked about this.
- 19:28SPEAKER_06: It's an oral therapy, once a day pill.
- 19:31SPEAKER_06: And so to be able to tell patients that as early as day two, they could actually start to have a symptomatic response.
- 19:38SPEAKER_06: And this was seen in almost 17% of patients on a trazomod compared to 11% of placebo.
- 19:45SPEAKER_06: On the right hand side, when we look at symptomatic remission, this became statistically significant with atrazmod by day 11, with over 13.5% of patients on a trazomod achieving that compared to 8.7% of placebo.
- 19:59SPEAKER_06: As Dr.
- 19:59SPEAKER_06: Steinberg called out with Ozanomod, we also note with these graphs the continued symptomatic improvement and the continued symptomatic remission that we see through day 28 with persistent widening from the atrazzma-treated patients to the placebo arm.
- 20:16SPEAKER_01: So, Kim, this is a fabulous overview.
- 20:18SPEAKER_01: And I do want to highlight what you said and what Josh said, which was telling patients when they might expect to notice a difference and when they might feel better is a really important way to communicate how the therapy works and also to set expectations so they don't expect that they're perfect by the end of the first week, but many people do feel better and they know they're on the right track that fast.
- 20:42SPEAKER_01: So now let's go on to part two, which is talking more about safety.
- 20:45SPEAKER_01: And of course, whenever we think about new mechanisms, we also want to understand the safety of that therapy and the potential effects versus the side effects.
- 20:56SPEAKER_01: And so let's talk a bit about the safety profile.
- 21:00SPEAKER_01: And let me put this in context for everyone.
- 21:02SPEAKER_01: There are the expected effects of this particular mechanism, and then there are some known side effects, and then there are rare off-target effects that may occur.
- 21:15SPEAKER_01: And so I'm going to do my best to make sure it's clear for folks.
- 21:19SPEAKER_01: The first one I want to say is that it's expected that the circulating lymphocytes in patients who are on these therapies will drop when you're taking this therapy.
- 21:29SPEAKER_01: And that's simply because you are sequestering the activated lymphocytes in lymph nodes.
- 21:36SPEAKER_01: So, in fact, what you see in the clinical trials and what you'll see in practice with patients who start these therapies is that their lymphocyte count in the periphery, when you get a white blood cell count with a CBC, is going to drop.
- 21:50SPEAKER_01: It does not drop to the level of causing infections.
- 21:55SPEAKER_01: This has been seen across the class, and it's important to know, but you will see that drop.
- 22:00SPEAKER_01: As an effect of the medication.
- 22:03SPEAKER_01: What are the other potential effects of this medicine?
- 22:07SPEAKER_01: S1P3, which is not what either ozonomod or atrosomod targets, is an uh sphingosine 1 phosphate receptor that's involved in cardiac conduction.
- 22:21SPEAKER_01: So some patients have an off-target effect of a transient, asymptomatic first dose bradycardia that goes away by the time they're on the second or third dose.
- 22:33SPEAKER_01: I want to emphasize again, transient, asymptomatic drop by a couple beats per minute.
- 22:40SPEAKER_01: That does not persist and doesn't cause other problems.
- 22:44SPEAKER_01: That is a known effect of the medication when it has an off-target effect, which we see with all of our meds.
- 22:50SPEAKER_01: It's important to understand this so you can put it in context.
- 22:54SPEAKER_01: This is why we recommend, and it is in the label, to know that your patient has sinus rhythm and doesn't have type 2 heart block.
- 23:03SPEAKER_01: Type 1 is okay, and we'll talk more about that.
- 23:06SPEAKER_01: It's also important to understand why ozonomod manage this by having a blister pack and a dose titration for the first week, where the patient gets a quarter of the dose of ozonomod, a half a dose, and then they're at full dose and they continue on that dose for the remainder of induction and into maintenance.
- 23:25SPEAKER_01: Trossomod doesn't do this actually.
- 23:27SPEAKER_01: Starts at two milligrams once a day for induction and then into maintenance, and there's no need for that dose titration.
- 23:34SPEAKER_01: So that's an important distinction.
- 23:36SPEAKER_01: There are known mild liver enzyme elevations.
- 23:40SPEAKER_01: They usually resolve over time.
- 23:43SPEAKER_01: They reflect the active metabolism of the drug, and they get better when the patient stays on therapy.
- 23:49SPEAKER_01: They have not resulted in liver failure or other concerns.
- 23:53SPEAKER_01: The rare off-target effects that we want to mention and teach about are something called macular edema, or more specifically, cystoid macular edema.
- 24:03SPEAKER_01: This is essentially leakage of fluid in the macula and in the retina.
- 24:09SPEAKER_01: It is not irreversible, and often we end up treating through it.
- 24:14SPEAKER_01: We're going to learn a little bit more about this.
- 24:16SPEAKER_01: The patients who are at risk for this rare side effect are those who have known eye problems.
- 24:21SPEAKER_01: Your patient with diabetes and who may have retinopathy, or patient with prior uveitis, for example.
- 24:28SPEAKER_01: There are rare side effects that can cause elevated blood pressure.
- 24:33SPEAKER_01: So monitoring that and keeping an eye on it.
- 24:35SPEAKER_01: More often in people with known hypertension, not in your young, healthy people who you might be considering this for.
- 24:42SPEAKER_01: And at least reported across the class, but not with these drugs, has to do with a class warning related to screening for skin cancer.
- 24:50SPEAKER_01: Remember that in IBD, we recommend screening for skin malignancies as a routine aspect of everyone who has IBD, and it's associated with any therapies we've had patients on previously or currently.
- 25:04SPEAKER_01: So that is something to know about, but it hasn't actually been seen with ozonomot or atrosomod, but it has been in the label that we would want to make sure we keep people screened, and it's part of what we do anyway.
- 25:16SPEAKER_01: What has not been observed in the trials with ozonomod and atrosomod are an increase in serious or opportunistic infections, an increase in malignancies, otherwise, or development of type two or third-degree heart block that doesn't happen.
- 25:33SPEAKER_01: And thankfully, there haven't been any deaths in the elevate trials and with these therapies.
- 25:39SPEAKER_01: So I wanted to put this in context before we dig in a little bit more.
- 25:43SPEAKER_01: And now we're going to have the opportunity to understand a bit more.
- 25:47SPEAKER_01: So, Josh, can you walk us through the cardiac assessment for these patients?
- 25:52SPEAKER_08: Certainly.
- 25:52SPEAKER_08: So what's novel or unique to S1P receptor modulators is some of this prerequisite assessment, which would include a baseline ECG.
- 26:01SPEAKER_08: Typically, this is a one-time assessment to look for any conduction abnormalities that we'll highlight further in this discussion.
- 26:09SPEAKER_08: First and foremost, if a patient has a normal ECG and there's no cardiac conduction or uh rhythm abnormalities, we do not have to refer to a cardiologist and we reassure the patient that based on the absence of any underlying cardiac or cardiovascular disease, we do not need to have great concern about any potential side effects or adverse events related to their S1P.
- 26:32SPEAKER_08: That being said, if we do find some irregularities, then we might need to consult with our cardiology colleagues to determine whether or not this treatment would be appropriate for this particular patient.
- 26:45SPEAKER_08: First and foremost, as Dr.
- 26:46SPEAKER_08: Rubin alluded to, there is a first dose bradycardia with these treatments, both with atrasomod as well as ozonomod.
- 26:54SPEAKER_08: You can see the mean heart rate drops, which are pretty low, maybe a reduction of 7.2 beats per minute in atrasomod patients, 0.7 in ozonomod patients.
- 27:03SPEAKER_08: Generally, these patients are asymptomatic, and this is a transient issue that resolves without any intervention for either agent.
- 27:10SPEAKER_08: Second degree or MOBIS type 1 AB blocks, this can be seen with atrasomod only.
- 27:15SPEAKER_08: You can see the incidence rates are quite low here, 0.7 to 0.8% on day one.
- 27:21SPEAKER_08: Again, these are typically transient and occurred only on day one in a tracemod patient and then resolved, and it's not been reported with those antibodym.
- 27:29SPEAKER_08: So if you get a baseline ECG and there's no abnormalities, certainly you can proceed.
- 27:34SPEAKER_08: If you see a patient that has a first degree A-B block alone, the patient can still proceed with treatment.
- 27:40SPEAKER_08: This is not a contraindication to start either S1P receptor or modulator.
- 27:44SPEAKER_08: Now, if a patient has borderline bradycardia with a heart rate of 50 to 54, you may want to talk with your cardiology colleagues to get input on whether this patient might be symptomatic or if there's any other risk factors where an S1P might be prohibitive to starting.
- 27:59SPEAKER_08: If a patient has significant QTC interval prolongation greater than 450 or so, certainly you'd want to consult your cardiologists before initiating treatment.
- 28:09SPEAKER_08: And if a patient on a baseline ECG, if they have a MOBITS type 2 or a third degree AB block, which would be very unusual in your otherwise healthy patient that you see in your IBD clinic, then certainly this particular S1P receptor modulator class would be contraindicated.
- 28:26SPEAKER_08: But what I can say is that in my practice, that many of these patients, most of these patients that you're getting this based on assessment will not have any abnormalities that are going to need further cardiac or cardiology assessment.
- 28:38SPEAKER_08: And if they do, then certainly we will move them along to get evaluated by a cardiologist, but this is few and far between.
- 28:46SPEAKER_08: We also asked Dr.
- 28:48SPEAKER_08: Tamar Polanski, a cardiologist at the University of Chicago, to weigh in on this directly.
- 28:54SPEAKER_05: So hi everybody, I'm Tammy Polansky.
- 28:56SPEAKER_05: I'm a general cardiologist at the University of Chicago.
- 28:59SPEAKER_05: I take care of people in the inpatient and outpatient setting, and I also do work in clinical trials.
- 29:06SPEAKER_05: So who are the uh generally healthier patients where healthcare providers could start these medications without referral to a cardiologist?
- 29:14SPEAKER_05: So that's going to be a patient with a heart rate above 55, a resting heart rate, someone who doesn't have significant abnormalities in terms of the heart rate on the EKG.
- 29:25SPEAKER_05: First degree AV block is actually just fine.
- 29:27SPEAKER_05: That would not be an exclusion.
- 29:29SPEAKER_05: Just higher degree AV block is something that would warrant a referral to a cardiologist.
- 29:34SPEAKER_05: First degree AV block is common even in younger people if they're really fit because they have high vagal tone.
- 29:41SPEAKER_05: And even people with lower resting heart rates in the low 50s can usually be fine to start these medications because that's actually often a sign of cardiovascular health.
- 29:52SPEAKER_05: These are usually people who are physically active, and so you can even ask them about their activity if they're going out and exercising regularly.
- 30:00SPEAKER_05: Again, that heart rate is a sign of cardiovascular health, even in the low 50s.
- 30:05SPEAKER_05: I would just caution against using any data from people's Apple Watches or Fitbits, they're incorporating, if they're telling you about their heart rate when they're sleeping, it's completely normal for people's heart rate to get quite slow when they sleep, much lower than 50.
- 30:21SPEAKER_05: And so it's really important to only use that resting heart rate when they're awake, because I would not take into account slow heart rates when they're sleeping.
- 30:29SPEAKER_05: That that, as I said, is normal for it to go down.
- 30:33SPEAKER_08: Thank you, Dr.
- 30:34SPEAKER_08: Polanski, for that input.
- 30:36SPEAKER_08: That was very valuable.
- 30:37SPEAKER_08: Uh next, we'll move on to some of the ophthalmic assessments for our patients who are starting S1P receptor modulators.
- 30:45SPEAKER_01: Thanks, Josh.
- 30:46SPEAKER_01: That was great.
- 30:46SPEAKER_01: And thanks to Dr.
- 30:47SPEAKER_01: Polanski for helping us with this.
- 30:49SPEAKER_01: I know many of our gastro colleagues thought that they didn't have to worry about looking at EKGs anymore when they became gastroenterologists.
- 30:57SPEAKER_01: But the practical approach that we've been using has also been just looking at a rhythm strip when they're having their colonoscopy, for example, and printing that out and confirming sinus rhythm.
- 31:07SPEAKER_01: Now, as I mentioned, there are rare ophthalmologic considerations for off-target macular edema that may associate with these therapies.
- 31:15SPEAKER_01: But I want to put this in context.
- 31:17SPEAKER_01: The incidence of macular edema in the trials for ulcerative colitis with ozonomod and atrosomod was quite rare.
- 31:24SPEAKER_01: There were three patients with ozonomod treatment compared to zero with placebo who developed macular edema.
- 31:31SPEAKER_01: They all discontinued the ozonomod.
- 31:34SPEAKER_01: They all had complete resolution of this problem.
- 31:37SPEAKER_01: The atrosomod studies had two patients with it who received atrosomod, one on placebo, and one of three discontinued, but the other two continued treatment without interruption and all events resolved completely.
- 31:51SPEAKER_01: The timing of this is of interest.
- 31:52SPEAKER_01: Most reported cases emerge within the first three to four months of treatment, and there are no new signals in the follow-up, long-term follow-up of the true north open label extension that Josh mentioned already.
- 32:05SPEAKER_01: So the clinical context of this is that, of course, we should understand what it means, but you're looking for your patients who have a known eye issue previously or who might have risk for one.
- 32:15SPEAKER_01: And the recommendation has been to consider an ophthalmologic evaluation shortly after starting therapy or at some point.
- 32:23SPEAKER_01: If you have a patient who's already seeing an ophthalmologist, that's helpful.
- 32:27SPEAKER_01: And if you have someone who you haven't sent to one and they don't have any other risks, that's for you to understand further.
- 32:33SPEAKER_01: But let's hear this directly from an expert.
- 32:35SPEAKER_01: We've invited an ophthalmologist, Dr.
- 32:37SPEAKER_01: Tariq Bhati, to educate us about this.
- 32:42SPEAKER_00: My name is Dr.
- 32:43SPEAKER_00: Tarik Bhati.
- 32:44SPEAKER_00: I'm a neuroophthalmologist at Kaiser Permanente in Northern California.
- 32:48SPEAKER_00: Before we discuss what is maculedema, I think it's important to just briefly review the anatomy of the eye, in particular the retina.
- 32:55SPEAKER_00: The word macular originates directly from Latin, where it translates to spot, stain, or blemish.
- 33:00SPEAKER_00: The macula represents about 1 to 2% of the total retina's surface area, but contains 30% of the retinal ganglion cells and has the largest concentration of cones for central vision and represents approximately 50% of the primary visual cortex.
- 33:15SPEAKER_00: The fovea is the center of the macula and contains only the cones.
- 33:19SPEAKER_00: And as you remember, the photoreceptor cells, there's two types, the rods and the cones, rods being for night vision, cones being for central vision, and for day vision.
- 33:28SPEAKER_00: Now, maculedema is a very common eye problem encountered in ophthalmic practices.
- 33:35SPEAKER_00: It most commonly occurs after cataract surgery or as a complication of diabetes, but also frequently it is associated with uveitis, which is an inflammation of the eye.
- 33:44SPEAKER_00: Fortunately, S1P receptor modulator associated with maculedema is uncommon with an approximate 0.2% to 0.4% incidence, which translates to two to four out of every thousand people.
- 33:58SPEAKER_00: So very uncommon side effect of an S1P modulator receptor modulator.
- 34:05SPEAKER_01: He's obviously done a much better job explaining it to you than I did.
- 34:08SPEAKER_01: And it's great to hear his perspective.
- 34:10SPEAKER_01: And I really very much appreciate his uh contributions to this program.
- 34:15SPEAKER_01: So, Kim, let's close out this section with the dermatology considerations.
- 34:19SPEAKER_01: Can you help us with that?
- 34:21SPEAKER_06: Sure.
- 34:21SPEAKER_06: And Dr.
- 34:22SPEAKER_06: Rubin, I actually want to highlight something you mentioned before, which is just reminding clinicians that when we think about all patients with IBD, regardless of their therapy, we know at baseline patients with IBD can have an increased risk of skin cancer compared to those non-IBD patients.
- 34:36SPEAKER_06: So just doing the due diligence and recommending dermatology screening for all of our IBD patients.
- 34:41SPEAKER_06: But when we really get to the nitty-gritty in the S1Ps, as you said, there is a class reminder about the risk of skin cancers.
- 34:49SPEAKER_06: And so that is for both ozanomod and atrazomod.
- 34:53SPEAKER_06: I want to again put into perspective that we know that there are certain therapies that can increase the risk of skin cancer in our IBD patients.
- 35:00SPEAKER_06: For example, thiopurines have that strongest evidence for increased basal and squamous cell carcinomas.
- 35:06SPEAKER_06: So while skin cancers have been reported within the class, it is quite rare.
- 35:11SPEAKER_06: And again, as you pointed out, when we look at the actual clinical trials, there has not been any established increased risk with these S1P receptors in the UC clinical trials.
- 35:22SPEAKER_06: When we look at the label of who we're going to need to actually screen for the skin cancer risk and who needs a formal dermatology referral, it's really important that we think about that patient sitting in front of us who is having active, moderate severe UC.
- 35:38SPEAKER_06: We need to get their disease under control.
- 35:40SPEAKER_06: And what is their risk of skin cancer?
- 35:42SPEAKER_06: So we can see in the box there are certainly some patients that are higher risk and who actually may need to see a dermatologist.
- 35:49SPEAKER_06: These include patients with a prior skin cancer, significant cumulative sun exposure, those who have had prior thiopurine, as I mentioned, exposure.
- 35:59SPEAKER_06: We do want to refer those patients, but I want to remind you again, based on the label, this doesn't need to be done prior to initiation.
- 36:05SPEAKER_06: It can be prior to or shortly after initiation of therapy.
- 36:09SPEAKER_06: In my practice, and I'm going to assume in both your practices, the majority of our patients with IBD are going to fall into this low risk category.
- 36:17SPEAKER_06: And so what does that mean for real world?
- 36:19SPEAKER_06: It means that they have no prior skin cancer, they don't have any significant risk factors.
- 36:23SPEAKER_06: And what we can do is just a basic skin inspection, which we should be doing when we examine our patients anyway, and taking a really good history about their or their family history of skin cancers.
- 36:34SPEAKER_06: Once we have actually done that, we then can go on and initiate therapy.
- 36:39SPEAKER_06: So again, it's really important that we think about what percent of our patients are really high risk.
- 36:43SPEAKER_06: And again, the majority of these patients are low risk for skin cancer.
- 36:47SPEAKER_06: And so we want to remember for them it's a basic skin inspection.
- 36:50SPEAKER_06: And then for all of our IBD patients, we really want to educate them on sun protection and routine skin exams.
- 36:58SPEAKER_06: So now we're going to look at one of our dermatologists has to say, Dr.
- 37:01SPEAKER_06: Ahuva Sisis.
- 37:05SPEAKER_02: I'm Ahuva Sisis, assistant professor of dermatology at the Icon School of Medicine at Mount Sinai and co-director of our IBD Derm Clinic.
- 37:14SPEAKER_02: I can say that from my experience seeing patients with S1P inhibitors, that it's really not impacted their health in terms of, you know, their skin health is something that we're monitoring, but it's really not caused any issues.
- 37:27SPEAKER_02: It's a very safe medication for our patients when it comes to their skin.
- 37:32SPEAKER_02: This is not something where I'm overly concerned about the risk of skin cancer, where I tend to kind of, you know, try and influence patients in terms of their tears, the thyoparines.
- 37:42SPEAKER_02: We really know that that has a tremendous impact on the development of non-melanoma skin cancers.
- 37:46SPEAKER_02: Certainly with uh TNF inhibitors, JAC inhibitors, there is some level of discussion and how this can potentially increase the risk of skin cancers.
- 37:55SPEAKER_02: But especially, you know, when we think about 23 inhibitors, S1P inhibitors, we're not seeing that in our data.
- 38:02SPEAKER_02: And so that's something that we'll continue to monitor over time and that there may be more data that we'll have to look at in the future.
- 38:09SPEAKER_02: But at this point, we're really not seeing those safety concerns and signals.
- 38:13SPEAKER_02: And so I find that that's really reassuring for my patients.
- 38:17SPEAKER_06: It is certainly helpful to hear how dermatology actually thinks through this.
- 38:23SPEAKER_01: What an amazing program to have our colleagues in cardiology, ophthalmology, and dermatology joining us for education and teaching all of us about these different aspects.
- 38:34SPEAKER_01: Let's now move to part three, all hands on deck.
- 38:37SPEAKER_01: And I want to start by just uh sharing what the ulcerative colitis guidelines have said about using our S1P receptor modulators.
- 38:45SPEAKER_01: I had a part to play in the 2025 American College of Gastroclinical Guidelines for patients with ulcerative colitis, specifically adults, and we had a strong recommendation based on the level of evidence for the use of S1P receptor modulators, specifically ozonomod and atrosomod, for the induction of remission and moderately to severely active UC, as well as continuing them in maintenance phase if the patient responded.
- 39:14SPEAKER_01: And so we made the points here that these are appropriate therapies, and they were on the same level as the strong recommendations and grading of the evidence as our other classes, including our JAC inhibitors and, of course, our monoclonal antibodies that are approved and available for the treatment of moderately to severely active UC.
- 39:33SPEAKER_01: So, Josh, why don't you highlight a couple of the practical differences between ozonomod and atrosomod?
- 39:39SPEAKER_01: We've touched on some of these, but let's round that out.
- 39:42SPEAKER_08: Certainly.
- 39:43SPEAKER_08: So to remind everyone, we have two S1Ps that are actively approved for moderate severely active ultraclitis.
- 39:49SPEAKER_08: With ozonomod, we see receptor selectivity to S1P1 and 5.
- 39:53SPEAKER_08: Itrosomod has those two, as well as S1P4.
- 39:56SPEAKER_08: As Dr.
- 39:57SPEAKER_08: Ruben pointed out, with ozonomod, we do have a seven-day titration that is required to reach a therapeutic daily dose, whereas with hetrosomod, there is no titration.
- 40:06SPEAKER_08: It's a therapeutic dose once a day from day one.
- 40:09SPEAKER_08: Ozonomod does have active metabolites.
- 40:11SPEAKER_08: The half-life is about 11 days for its major metabolite, whereas atrasomod has no major active metabolite, so it's short, its half-life is much shorter, 29 to 36 hours.
- 40:21SPEAKER_08: Lymphocyte recovery after stopping.
- 40:23SPEAKER_08: Of course, this is an expected experience with reduction in lymphocytes with starting these treatments.
- 40:27SPEAKER_08: With ozonomod, up to 90% will recover after three months or within three months.
- 40:32SPEAKER_08: But the trostomid will be much sooner, 90% or so within the first four or five weeks after stopping.
- 40:38SPEAKER_08: There are some key drug-drug interactions that are listed here and similar across both ozonomod and atracemod, including MAOIs, which are contra-indicated, CYP2CA inhibitors, which we should monitor patients on, uh patients who might be on class 1A or two or three antiarrhythmics, and drugs that might slow heart rate or any AB conduction.
- 40:58SPEAKER_08: Contraception.
- 40:59SPEAKER_08: So currently these therapies are not indicated.
- 41:02SPEAKER_08: They're contra-indicated for patients who become pregnant or are breastfeeding, lactating.
- 41:07SPEAKER_08: Patients on ozanomod should stop this therapy at least three months prior to conception.
- 41:12SPEAKER_08: And then atrasomad patients, they should be off that therapy for at least one week.
- 41:17SPEAKER_08: It has a much more rapid offset before they initiate or try conception.
- 41:21SPEAKER_08: You can see the FDA approval dates here.
- 41:29SPEAKER_01: So this is a helpful comparison.
- 41:32SPEAKER_01: Are there any specific reasons you might choose one over another?
- 41:36SPEAKER_08: I think for convenience sake, atrasomod without that dose titration is nice.
- 41:40SPEAKER_08: Um, it's a little less confusing for some patients.
- 41:43SPEAKER_08: I do think the rapid half-life can come into play in certain scenarios.
- 41:48SPEAKER_08: And our patients, if there is some adverse effect that we encounter or if they might want to become pregnant, we, you know, we want to know in our female patients of childbearing age if they are planning to start a family.
- 42:01SPEAKER_08: And we have a little more wiggle room, so to speak, uh, given a much more rapid act uh path life with a Trasomod that we can stop and then give patients that reassurance that they can start uh to conceive it's a if it's appropriate for them and their disease idealism and remission after about a week or so.
- 42:18SPEAKER_08: So those are some practical uh indications.
- 42:21SPEAKER_08: Of course, insurance always plays a role in some of this too.
- 42:24SPEAKER_08: Um, but that's so those are some of the highlights I'd I'd call out there.
- 42:27SPEAKER_01: Yeah, I completely agree with you in terms of convenience and the wrap it on, wrap it off.
- 42:32SPEAKER_01: Um I would just point out one distinction that is worth mentioning again, which is ozonomod is also approved by the FDA for the treatment of relapsing and remitting multiple sclerosis.
- 42:43SPEAKER_01: So I do have a couple patients with ulcerative colitis who also have MS, where I work with their neurologist, and we have them on this therapy because of that additional label and availability.
- 42:55SPEAKER_01: So that might be one distinction that's helpful for people.
- 42:58SPEAKER_08: Absolutely.
- 43:00SPEAKER_08: Thank you, Dr.
- 43:01SPEAKER_08: Rubin.
- 43:01SPEAKER_08: Kim, can you provide some insight on what's required versus what's recommended for a zonomod and a chasmod from the prescribing information?
- 43:08SPEAKER_06: Of course.
- 43:09SPEAKER_06: Yeah, thanks, Dr.
- 43:10SPEAKER_06: Steinberg.
- 43:11SPEAKER_06: So as we discussed, either prior to or shortly after initiation, for the majority of our IBD patients, they are going to be low risk for skin cancer.
- 43:20SPEAKER_06: But we do want to ensure they at least get a basic skin exam that can be done with us in the GI clinic, with their primary care.
- 43:27SPEAKER_06: And then again, if it is a high-risk patient, making sure that we do get them in for a germ referral, but again, not holding therapy for that because it can be done shortly after initiation of therapy.
- 43:37SPEAKER_06: As we discussed, we're going to get this one time baseline ECG.
- 43:42SPEAKER_06: And then, if needed, which we talked about, is going to be quite rare in our IBD patient population, that cardiology consult.
- 43:48SPEAKER_06: When we talk about labs for patients with IBD, I think the ones that are required for these therapies are pretty standard.
- 43:54SPEAKER_06: We want to make sure we have that CBC with diff, that lymphocyte count, as well as LFT.
- 44:00SPEAKER_06: Use within the last six months prior to initiation of therapy.
- 44:03SPEAKER_06: I usually add into my labs at this time as well a varicella antibody if patients cannot confirm that they have had chickenpox or already been vaccinated.
- 44:13SPEAKER_06: I learned something from Dr.
- 44:14SPEAKER_06: Rubin before this that I wanted to highlight, which is that only about 5% of adults in the US are actually still susceptible to varicella.
- 44:24SPEAKER_06: The other thing that is actually unique compared to some of our IBD advanced therapies is it is not required to screen for tuberculosis or hepatitis.
- 44:33SPEAKER_06: Dr.
- 44:33SPEAKER_06: Steinberg, you did a really good job talking about kind of how long we're going to hold this due to half-life prior to conception.
- 44:39SPEAKER_06: So we do not need a pregnancy test.
- 44:41SPEAKER_06: We just want to educate these patients that we don't want them to get pregnant while they're on therapy, to use contraception during that time.
- 44:48SPEAKER_06: And again, as you mentioned, a slightly different one week where we're going to wait to conceive after discontinuing a Trazomod versus about that three months for ozenomod.
- 44:58SPEAKER_06: And then as we discussed, either prior to or near the start of treatment, just a baseline ophthalmic exam of the fundus.
- 45:08SPEAKER_01: Well, Kim, that's amazing.
- 45:10SPEAKER_01: And we've now covered all the basics.
- 45:12SPEAKER_01: Let's round this off with a couple cases and some questions for our audience.
- 45:17SPEAKER_01: So I'm going to present this case of Maria, who's 34 years old.
- 45:21SPEAKER_01: She has a history of ulcerative colitis for six years, and she currently has moderately to severely active disease.
- 45:27SPEAKER_01: Her endoscopic subscore is a three out of three.
- 45:31SPEAKER_01: And she's had an inadequate response to a prior TNF inhibitor.
- 45:35SPEAKER_01: She has no history of eye problems and she does not have diabetes.
- 45:39SPEAKER_01: Her vaccination records are incomplete.
- 45:42SPEAKER_01: And she and her gastrologist are now considering an S1P receptor modulator therapy, given what we know about this drug and the availability of it for her.
- 45:52SPEAKER_01: So now we know Maria's history.
- 45:53SPEAKER_01: Let's think through what her workup should look like.
- 45:57SPEAKER_01: So what should she do now?
- 45:59SPEAKER_01: And what do you think would be the appropriate strategy?
- 46:02SPEAKER_01: Should it be A, she should try one or more additional advanced therapies before she gets to the S1P receptor modulator?
- 46:10SPEAKER_01: Should it be B, efficacy data support S1P receptor modulator use in patients with an inadequate response to a prior biologic, including sustained benefit through one year?
- 46:22SPEAKER_01: C, S1P receptor modulator therapy is only appropriate for patients naive to advanced therapy.
- 46:29SPEAKER_01: D, the baseline testing standards make her a poor candidate for this therapy.
- 46:34SPEAKER_01: Or E, I don't know, which is a fair answer if you're still learning.
- 46:57SPEAKER_01: So which is the right answer here?
- 46:59SPEAKER_01: Well, the right answer is B.
- 47:02SPEAKER_01: It is true that this is an available therapy, and it absolutely has data to support its use in patients who've had an inadequate response to a prior biologic, including anti-TNFs, with subsequent sustained benefit through one year.
- 47:16SPEAKER_01: So while we've acknowledged that this is an excellent option, it is a first-line advanced therapy.
- 47:22SPEAKER_01: It also is approved and available and has good evidence that it can be used after an advanced therapy as well.
- 47:29SPEAKER_01: So, Josh, let's look at how to translate these assessments into referral decisions.
- 47:34SPEAKER_01: Does she need to see other doctors as part of this plan?
- 47:38SPEAKER_08: Absolutely.
- 47:39SPEAKER_08: So first and foremost, I'll remind our audience that most of your patients are not going to need referrals to subspecialists.
- 47:46SPEAKER_08: Some will.
- 47:47SPEAKER_08: So let's talk about that.
- 47:49SPEAKER_08: From the baseline ECG, let's talk about whether or not a patient might need a cardiology assessment.
- 47:54SPEAKER_08: If they have a first degree AV block alone, or if they're asymptomatic, have a stable cardiovascular history, a normal ECG, a baseline heart rate of at least 55 with a ZANMOD or at least 50 with a TRASMOD, we can proceed with initiating their S1P receptor modulator.
- 48:08SPEAKER_08: When we should refer to cardiology would include patients with MOBITS type two or type three heart blocks, six sinus, SA blocks, patients who have had a recent history of MI stroke TRA within the last six months, or to compensate an advanced heart failure.
- 48:26SPEAKER_08: Those with resting bradycardia, again, those heart rates are listed there, or a history of MOBIDS type one, particularly in those patients that you're thinking about starting a trausmod, or an a QTC prolongated patient, more than 450 in men or more than 470 in women.
- 48:41SPEAKER_08: When might your patient need an ophthalmology referral?
- 48:44SPEAKER_08: Well, they will not need one if they have no history of diabetes or uveitis or any visual symptoms.
- 48:49SPEAKER_08: And if a baseline ophthalmology exam, which is routine and can be a low acuity visit near the start of their treatment, they can go ahead and proceed if there's no concerns there.
- 48:58SPEAKER_08: One was should refer to an ophthalmologist, a patient with a known history of diabetes and maladies type 1 or 2, a history of uveitis, any baseline visual symptoms or known retinal disease or any vision change during their S1P treatment.
- 49:12SPEAKER_08: Now to skin dermatology.
- 49:14SPEAKER_08: In a patient with no prior skin cancer or significant UV exposure or risk factors, and a patient with a basic skin inspection and history by us are the GIs or a PCP, then they can certainly proceed if there's no concerns on that baseline exam around the time of initiation.
- 49:30SPEAKER_08: You should refer to a dermatologist if they've had a history of prior skin cancer that would include basal, squamous, or melanoma.
- 49:36SPEAKER_08: If they have had significant cumulative UV exposure with any atypical Neve, prior thyropurine or PUVA exposure or any suspicious lesion at baseline or during treatment that you might encounter in your patients on an S1P, at that point you should refer to a dermatologist.
- 49:53SPEAKER_01: Thanks, Josh.
- 49:53SPEAKER_01: That's really helpful.
- 49:54SPEAKER_01: And I just want to highlight for folks that most of the things that we would consider referral are pre-existing problems that they probably are already seeing the specialist.
- 50:03SPEAKER_01: So it's just about communication.
- 50:05SPEAKER_01: And I'll just say to you that in our experience using these therapies, I have almost never needed to refer to these other individuals separate from what they may already be doing, or they just don't have any risk factors and we manage this.
- 50:19SPEAKER_01: So let's bring this all together with understanding the workflow itself.
- 50:23SPEAKER_01: So, Kim, can you tell us a little bit about how this might work in a practice in terms of all the different members of our team working together?
- 50:31SPEAKER_06: Sure.
- 50:32SPEAKER_06: I think the first part is certainly making sure we identify the patients who could benefit from S1P therapy and really not letting the process feel overwhelming because it's really not.
- 50:43SPEAKER_06: And hopefully I can break it down a little bit further.
- 50:46SPEAKER_06: So if we think about it again, we're going to identify that patient with moderate to severely active UC.
- 50:51SPEAKER_06: We want to talk to the patient about how we're going to do some baseline or screening tests as we do for any advanced therapy.
- 50:58SPEAKER_06: We're going to coordinate next when the patient is in office with either our medical assistant, our IBD nurse, our coordinator to make sure that they get the labs, the ECG, the macular exam done.
- 51:10SPEAKER_06: And again, we often are able to do just that skin exam and make sure that there's nothing concerning.
- 51:17SPEAKER_06: So just like with all of our advanced therapies, again, the biggest thing is really making sure that they've had these labs and coordinating all of that.
- 51:25SPEAKER_06: As mentioned, and I just want to kind of echo this again, is it's very rare.
- 51:29SPEAKER_06: And in my practice, I don't know that I've really had to refer for specialists for this.
- 51:34SPEAKER_06: And there are also some programs based on which therapy we're using and also patients' coverage.
- 51:40SPEAKER_06: Some of these are able to be done with some support for the patients.
- 51:43SPEAKER_06: And so again, it's really us as providers determining the patient and that this is a really good therapy for them, making sure that we order the screening labs, again, that ECG ECG, and then really working to make sure we get those results and get these patients on therapy, keeping in mind that getting their disease control is really the most important thing.
- 52:03SPEAKER_01: This is super helpful.
- 52:04SPEAKER_01: And I want to emphasize that another major theme in IBD advancement has been avoiding corticosteroids altogether.
- 52:11SPEAKER_01: So you showed us steroid sparing data with atrosomod earlier.
- 52:15SPEAKER_01: And we certainly know that with Ozana Mod as well.
- 52:17SPEAKER_01: But I want to highlight that if you know your patient's going to be moving through this process with your team working together, skip the steroids.
- 52:25SPEAKER_01: Let them get started on the drug and get the full benefit of it without having to worry about that.
- 52:30SPEAKER_06: And I think to follow that, Dr.
- 52:32SPEAKER_06: Rubin, we showed really that onset of efficacy sometimes being days in our patients, right?
- 52:36SPEAKER_06: So another reason that hopefully we can spare them from that steroid.
- 52:41SPEAKER_06: So with that, now it's a great time to get our registered nurses' perspective.
- 52:45SPEAKER_06: We're going to hear what Jacqueline Gianni has to say.
- 52:50SPEAKER_04: Hi, my name is Jacqueline Gianni.
- 52:52SPEAKER_04: I'm a registered nurse at the University of Chicago Medicine.
- 52:56SPEAKER_04: I am a nurse in the GI clinic and work specifically with IBD patients for the last eight years.
- 53:04SPEAKER_04: And I've been a registered nurse for almost 10 years.
- 53:08SPEAKER_04: As an IVD nurse, having collaboration between the nursing team, the doctors, and I think the pharmacist is really important in order to initiate this, you know, medication.
- 53:21SPEAKER_04: I think one thing that's important is to make sure that everyone kind of knows what their role is in the process.
- 53:29SPEAKER_04: But I think making sure that each person knows what they're doing.
- 53:33SPEAKER_04: So then, you know, the work's not being missed or duplicated.
- 53:37SPEAKER_04: And then that way we also we can try to get the insurance approval in a timely manner and get the patient started on the medication as soon as possible.
- 53:46SPEAKER_04: I think it, you know, again, making sure everyone knows their role and um helps avoid any confusion.
- 53:53SPEAKER_04: Um and we don't, you know, end up missing anything as well.
- 53:56SPEAKER_04: Um and then I think also just um as well working with um the rep the representatives from the the drug uh company as well.
- 54:06SPEAKER_04: They have you know a lot of good resources.
- 54:08SPEAKER_04: Um so if there's any questions about the process or the insurance approval or PA or anything like that, um they're always there to help and answer any questions as well.
- 54:19SPEAKER_06: Her perspective really brings the workflow to life and also makes us think about what our patients need to hear as well.
- 54:27SPEAKER_01: Jackie's so amazing, and we're very fortunate to learn from her.
- 54:30SPEAKER_01: And obviously I work with her, and so has Josh when he was training with us.
- 54:35SPEAKER_01: So we're happy to hear from her, and she makes our teamwork so much better.
- 54:41SPEAKER_08: Absolutely.
- 54:42SPEAKER_08: We miss Jackie.
- 54:45SPEAKER_06: And I think, you know, one of the main messages is patients want to hear what we just talked about.
- 54:50SPEAKER_06: They want to hear why we are choosing this medicine.
- 54:53SPEAKER_06: They want to hear about the efficacy, they want to hear about the rapidity of onset, they want to hear about the sustainable and durability when it comes to the efficacy as well as the safety of this therapy.
- 55:04SPEAKER_06: So again, it is really starting there and starting when we talk to patients about the benefit of the therapy and making sure we're not focusing on the process.
- 55:13SPEAKER_06: Because as I broke down to you, and as we heard from others, the process really shouldn't be overwhelming.
- 55:18SPEAKER_06: And the majority of our patients do not need to be referred outside of GI.
- 55:23SPEAKER_06: So again, we want to start with that patient education, how we want to get them better, how this is an oral therapy that has that really fast onset of action.
- 55:32SPEAKER_06: I always then am going to coordinate with my staff to make sure we have everything lined up for those screening labs and things.
- 55:38SPEAKER_06: And then, of course, we're gonna talk to our patients about reasonable expectations and when we're gonna see them back and how at that point when we see them back, we want to make sure they are having clinical improvement and we might do some monitoring of further labs to make sure that they're tolerating the therapy well.
- 55:54SPEAKER_06: To further provide insight from a real patient perspective, let's listen to Maya.
- 55:59SPEAKER_06: This is a medical student that was diagnosed with active ulcerative colitis during medical school.
- 56:07SPEAKER_03: Hi, I'm Maya.
- 56:08SPEAKER_03: Um, I'm 23 years old and I've grown up in the city of Chicago and the surrounding suburbs.
- 56:15SPEAKER_03: Um, I'm currently a second-year medical student.
- 56:18SPEAKER_03: Getting diagnosed as a student was quite the relief, honestly.
- 56:22SPEAKER_03: I was unsure about what was wrong for a bit of time.
- 56:26SPEAKER_03: And so finally having a diagnosis allowed me to come to terms with everything.
- 56:30SPEAKER_03: Um, and I had chosen to start an S1P because of my previously failed attempts with other medications.
- 56:36SPEAKER_03: Um, their methods of administration were less than ideal for my lifestyle, um, and I found that my symptoms relapsed pretty quickly.
- 56:43SPEAKER_03: Once I had started the S1P, I noticed symptom improvement as soon as three days and then almost complete resolution at nine, and have since been on it for three and a half months with a syndrome relapse, thankfully.
- 56:57SPEAKER_03: Prior to starting the medication, my doctor advised me to get an unexamin, blood work, and an AKG.
- 57:04SPEAKER_03: Um, initially I was a little bit nervous because that led me to believe that the medication could could cause side effects in one of those areas.
- 57:11SPEAKER_03: Um, but I was able, I was um relieved in hearing that it was more of a preventative measure and all of my tests were normal and medicines had no issues in any of those areas.
- 57:22SPEAKER_03: There was no strong moment before starting the medication that made me hesitant.
- 57:26SPEAKER_03: Um and I think that initially when I had heard about all of the testing that I was recommended, I was a little bit more hesitant only because of the hassle to get those exams rather than being too scared.
- 57:40SPEAKER_03: However, all of the exams were actually done in office that day.
- 57:43SPEAKER_03: So that kind of removed that obstacle from me.
- 57:46SPEAKER_03: And I was able to start the medication very shortly after that appointment.
- 57:51SPEAKER_06: I have to say, hearing that directly from a patient really puts all of this into perspective.
- 57:58SPEAKER_01: I completely agree and it reminds us why we do what we do.
- 58:02SPEAKER_01: So let's look at another audience response question to wrap up this section.
- 58:07SPEAKER_01: A patient has recently started a trostomod for moderately to severely active UC.
- 58:12SPEAKER_01: Which of the following best reflects a team-based approach to supporting this patient going forward?
- 58:18SPEAKER_01: A, the prescriber manages all follow-up independently once therapy has started.
- 58:23SPEAKER_01: B, the pharmacist role is limited to processing the refills.
- 58:27SPEAKER_01: C, the nurse coordinator, pharmacist, and prescriber each play an ongoing role, sharing responsibility for monitoring adherence, answering patient questions, and flagging any new symptoms that arise.
- 58:38SPEAKER_01: Similar team-based follow-up used for any IBD therapy.
- 58:42SPEAKER_01: D, no further coordination is needed unless the patient develops a new medical problem, or E.
- 58:48SPEAKER_01: I don't know.
- 59:08SPEAKER_01: I do know, and I think that this is fairly straightforward, but I hope everyone has a wonderful team and they recognize that the correct answer is C.
- 59:16SPEAKER_01: Your team continues to help.
- 59:18SPEAKER_01: Monitoring is as important a phase of management in IBD as is induction and getting people on maintenance therapy.
- 59:26SPEAKER_01: And so we work together, and that's of course what makes taking care of patients with IBD such a joy and successful.
- 59:34SPEAKER_01: So let's close with our final part cleared for takeoff, part four.
- 59:38SPEAKER_01: And this is going to take us from the evidence to the action.
- 59:42SPEAKER_01: Um, I want to just highlight the bottom line here.
- 59:45SPEAKER_01: We've covered efficacy, including ozonomod and atrosomod phase three trials.
- 59:50SPEAKER_01: We've discussed ACG guidelines, and there are similar guidelines from other societies.
- 59:56SPEAKER_01: We've reviewed safety, so hopefully you now understand with a unique mechanism comes some new learning tools for us, as well as understanding when we need to consider referral to experts to help us in this management.
- 1:00:09SPEAKER_01: And hopefully you've understood that in most cases that's not necessary.
- 1:00:14SPEAKER_01: And you've also learned about the importance of access, specialist access, as well as understanding the social determinants of health and being able to support our patients with their needs.
- 1:00:25SPEAKER_01: So let's test all of you with one final question.
- 1:00:29SPEAKER_01: Despite guideline support and robust trial data, S1P receptor modulary use for UC remains low relative to our other advanced therapies.
- 1:00:38SPEAKER_01: Which of the following best reflects the current evidence base for these agents?
- 1:00:43SPEAKER_01: A, efficacy is modest and best reserved as a fallback after biological therapies have failed.
- 1:00:49SPEAKER_01: B.
- 1:00:50SPEAKER_01: Trial data show robust efficacy limited mainly to short-term induction without durable benefit.
- 1:00:56SPEAKER_01: C.
- 1:00:57SPEAKER_01: S1P receptor modulators have demonstrated durable clinical, endoscopic, and mucosal efficacy through one year, including patients naive to advanced therapy, and are included among the 2025 ACG guidelines, recommended options for outpatients with moderately to severely active UC.
- 1:01:16SPEAKER_01: D, required baseline assessments are too burdensome to justify use in most patients.
- 1:01:21SPEAKER_01: Or E, I don't know.
- 1:01:41SPEAKER_01: And I'm sure if you're reading along with me, you know that the answer we were going for was C, that the evidence supports its use, the guidelines back that up, and we really are hopeful that you have learned and will consider this for appropriate patients going forward.
- 1:01:56SPEAKER_01: So, Josh, do you want to close us out with our SMART goals?
- 1:02:00SPEAKER_01: Absolutely.
- 1:02:01SPEAKER_08: So now that hopefully you all have the information and the tools and education that you need to start incorporating S1P receptor modulators into your IBD practice, we want to put this information into action.
- 1:02:12SPEAKER_08: And we can use SMART goals.
- 1:02:13SPEAKER_08: You might have heard about SMART goals.
- 1:02:14SPEAKER_08: SMART goals are specific, measurable, attainable, relevant, and timely.
- 1:02:19SPEAKER_08: Firstly, we want to increase confident initiation of S1P receptor modulator therapy in eligible patients with moderate to severely active pulsary colitis, including those naive to advanced therapy based on the current efficacy data that we demonstrated here today.
- 1:02:33SPEAKER_08: Number two, we want to improve appropriate application of cardiovascular, dermatologic, and ophthalmologic assessment tools to determine S1P receptor modulator eligibility, distinguishing patients who might require specialist referral from those who can proceed based on current safety data.
- 1:02:50SPEAKER_08: And lastly, we want to strengthen interprofessional team-based workflows for S1P receptor modulator initiation, clarifying roles across GI, nursing, and specialist partners to optimize referral coordination and timely treatment delivery so that your patients can get access to the therapy that might work well for them.
- 1:03:08SPEAKER_01: That's great, Josh.
- 1:03:09SPEAKER_01: Thank you for teaching us about the SMART goals.
- 1:03:11SPEAKER_01: We have a couple others just to round things out.
- 1:03:14SPEAKER_01: And that includes making sure that we're working well with our teams, establishing clear communication channels, and fostering this team approach that really can improve not only the way our patients are feeling, of course, but how we work and support each other, a commitment to evidence-based practices, and of course, respect for other healthcare providers and professionals, unique knowledge and contributions.
- 1:03:38SPEAKER_01: You'll also want to assess collaboration competency and willingness to accept feedback from other colleagues in your practice and on your team.
- 1:03:46SPEAKER_01: Understand that patient and caregiver values, preferences, and needs are considered by everyone on your team, and this is worth reminding folks at times.
- 1:03:54SPEAKER_01: And use frameworks for structured communication, which are available.
- 1:03:58SPEAKER_01: There are additional resources.
- 1:04:00SPEAKER_01: You can go to www.cmeoutfitters.com for clinical information and other certified educational activities like this one.
- 1:04:10SPEAKER_01: And you can go to the gastroenterology hub there as well for free resources in education for your team colleagues and for your patients.
- 1:04:21SPEAKER_01: To receive CE or CME credit for your participation in this program, you'll need to complete the post-test and evaluation online.
- 1:04:29SPEAKER_01: I hope that you, like I, have found this to be a very valuable resource.
- 1:04:34SPEAKER_01: I personally truly enjoyed working with my colleagues, Dr.
- 1:04:37SPEAKER_01: Josh Steinberg and Kimberly Orlick, our fabulous APP, learning about this together, but also all the comments from our expert colleagues who provided videos, our registered nurse, uh Jackie, as well as our incredible patient Maya, who shared her story.
- 1:04:55SPEAKER_01: Thank you all so much for joining us today.
- 1:04:58SPEAKER_06: Thanks, Dr.
- 1:04:59SPEAKER_06: Ruben.